Daniela E Matei

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation
    Daniela Matei
    Department of Medicine, Walther Oncology Center, Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 10:681-90. 2004
  2. ncbi request reprint Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer
    D Matei
    Indiana University Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Oncogene 25:2060-9. 2006
  3. ncbi request reprint PDGF BB induces VEGF secretion in ovarian cancer
    Daniela Matei
    Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer Biol Ther 6:1951-9. 2007
  4. doi request reprint Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism
    Salvatore Condello
    1D M, Indiana University Simon Cancer Center, 535 Barnhill Dr, RT 473, Indianapolis, IN 46202, USA
    FASEB J 27:3100-12. 2013
  5. doi request reprint Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer
    Minghai Shao
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Mol Cancer Ther 11:1576-86. 2012
  6. pmc Epigenetic resensitization to platinum in ovarian cancer
    Daniela Matei
    Melvin and Bren Simon Cancer Center, Indiana University, Bloomington, Indiana 46202, USA
    Cancer Res 72:2197-205. 2012
  7. pmc Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial
    Daniela Matei
    Indiana University School of Medicine, Division of Hematology Oncology, RT 457, 535 Barnhill Dr, Indianapolis, IN 46202, USA
    J Clin Oncol 29:69-75. 2011
  8. pmc Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
    Daniela E Matei
    Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 116:195-201. 2010
  9. pmc Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study
    Daniela Matei
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive RT 473, Indianapolis, IN 46202, USA
    J Clin Oncol 27:4142-9. 2009
  10. doi request reprint Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial
    Daniela Matei
    Indiana University Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 115:90-6. 2009

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation
    Daniela Matei
    Department of Medicine, Walther Oncology Center, Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 10:681-90. 2004
    ....
  2. ncbi request reprint Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer
    D Matei
    Indiana University Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Oncogene 25:2060-9. 2006
    ..Specific PDGFR inhibition by siRNA or a neutralizing antibody to the receptor inhibited PDGF-stimulated receptor activation and cell proliferation, suggesting that receptor targeting has a role in ovarian cancer treatment...
  3. ncbi request reprint PDGF BB induces VEGF secretion in ovarian cancer
    Daniela Matei
    Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer Biol Ther 6:1951-9. 2007
    ..The effects of imatinib on VEGF secretion in tumor cells may affect the tumor microenvironment in a manner detrimental to tumor progression...
  4. doi request reprint Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism
    Salvatore Condello
    1D M, Indiana University Simon Cancer Center, 535 Barnhill Dr, RT 473, Indianapolis, IN 46202, USA
    FASEB J 27:3100-12. 2013
    ..Condello, S., Cao, L., Matei, D. Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism. ..
  5. doi request reprint Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer
    Minghai Shao
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Mol Cancer Ther 11:1576-86. 2012
    ..This study provides the rationale for designing bevacizumab-based combination regimens to enhance antitumor activity...
  6. pmc Epigenetic resensitization to platinum in ovarian cancer
    Daniela Matei
    Melvin and Bren Simon Cancer Center, Indiana University, Bloomington, Indiana 46202, USA
    Cancer Res 72:2197-205. 2012
    ....
  7. pmc Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial
    Daniela Matei
    Indiana University School of Medicine, Division of Hematology Oncology, RT 457, 535 Barnhill Dr, Indianapolis, IN 46202, USA
    J Clin Oncol 29:69-75. 2011
    ..CONCLUSION Sorafenib has modest antitumor activity in patients with recurrent OC, but the activity was at the expense of substantial toxicity...
  8. pmc Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
    Daniela E Matei
    Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 116:195-201. 2010
    ....
  9. pmc Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study
    Daniela Matei
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive RT 473, Indianapolis, IN 46202, USA
    J Clin Oncol 27:4142-9. 2009
    ..This study compares late effects of treatment on physical well-being and utilization of health care resources between ovarian germ cell tumor (OGCT) survivors and age/race/education-matched controls...
  10. doi request reprint Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial
    Daniela Matei
    Indiana University Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 115:90-6. 2009
    ..This study was conducted to determine the activity and safety of 2ME2 administered as a NanoCrystal dispersion (NCD) formulation in patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC)...
  11. doi request reprint Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial
    Daniela Matei
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer 113:723-32. 2008
    ..This study was conducted to determine the activity of imatinib in combination with docetaxel in patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC)...
  12. ncbi request reprint The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells
    Daniela Matei
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Biol Chem 282:445-53. 2007
    ..These results show that 17-AAG promotes PDGFRalpha degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG...
  13. ncbi request reprint Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase
    Minati Satpathy
    Department of Medicine, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Cancer Res 67:7194-202. 2007
    ..Highly expressed in ovarian tumors, TG2 facilitates i.p. tumor dissemination by enhancing cell adhesion to the extracellular matrix and modulating beta(1) integrin subunit expression...
  14. ncbi request reprint Novel agents in ovarian cancer
    Daniela Matei
    Indiana University School of Medicine, Division of Hematology Oncology, Indianapolis, IN 46202, USA
    Expert Opin Investig Drugs 16:1227-39. 2007
    ..Individualized treatment driven by molecular characteristics will open the door to a new age in anticancer medicine...
  15. pmc A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
    Fang Fang
    Medical Sciences Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer 116:4043-53. 2010
    ....
  16. doi request reprint Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase
    Minghai Shao
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer Res 69:9192-201. 2009
    ..Highly expressed in ovarian tumors, TG2 promotes EMT and enhances ovarian tumor metastasis by activating oncogenic signaling...
  17. pmc N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients
    William R Alley
    Department of Chemistry, Indiana University, Bloomington, Indiana, United States
    J Proteome Res 11:2282-300. 2012
    ..In some cases, the pre-treatment samples could be distinguished from the post-experimental treatment samples, as many of those patients showed a further progression of the disease...
  18. doi request reprint Role of epigenomics in ovarian and endometrial cancers
    Curtis Balch
    Medical Sciences Program, Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Jordan Hall 302, 1001 East Third Street, Bloomington, IN 47408, USA
    Epigenomics 2:419-47. 2010
    ....
  19. pmc Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity
    Minati Satpathy
    Indiana University Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Biol Chem 284:15390-9. 2009
    ..The demonstration that TG2 induced degradation of PP2A-alpha activates CREB, and thereby increases MMP-2 transcription, provides novel mechanistic insight into the pro- metastatic function of TG2...
  20. pmc Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling
    Liyun Cao
    Department of Medicine, Richard L Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Carcinogenesis 29:1893-900. 2008
    ..Our data show that TG2 prevents apoptosis induced by cisplatin by activating the NF-kappaB survival pathway in ovarian cancer cells...
  21. pmc Minireview: epigenetic changes in ovarian cancer
    Curt Balch
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405 4401, USA
    Endocrinology 150:4003-11. 2009
    ..A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy...
  22. pmc Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis
    Lisa M Hess
    Department of Public Health, Indiana University School of Medicine, Indianapolis, IN, USA
    Cancer 116:5251-60. 2010
    ....
  23. ncbi request reprint Breast mass in a patient with ovarian cancer: a case report
    Suresh Gayathri
    Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    J Reprod Med 54:639-44. 2009
    ..Gynecologic tumors rarely metastasize to the breast. We report 2 patients who developed a breast mass following a known diagnosis of metastatic ovarian carcinoma or primary peritoneal carcinoma...
  24. pmc Identification and characterization of ovarian cancer-initiating cells from primary human tumors
    Shu Zhang
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405, USA
    Cancer Res 68:4311-20. 2008
    ..Based on these findings, we assert that epithelial ovarian cancers derive from a subpopulation of CD44(+)CD117(+) cells, thus representing a possible therapeutic target for this devastating disease...
  25. ncbi request reprint Gene expression in epithelial ovarian carcinoma
    Daniela Matei
    Department of Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, California, CA 90095, USA
    Oncogene 21:6289-98. 2002
    ..Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner...
  26. ncbi request reprint Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility
    Lindsay Gillan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Cancer Res 62:5358-64. 2002
    ..We propose PN functions as a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins to support adhesion and migration of ovarian epithelial cells...
  27. doi request reprint Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase
    May Khanna
    Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 535 Barnhill Drive, RT473, Indianapolis, IN 46202, USA
    Mol Cancer Ther 10:626-36. 2011
    ..This suggests a potential allosteric mechanism for the compound in light of its distal target site...
  28. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...